# onlinesermorelin.com # onlinesermorelin — sermorelin(7) — synthetic 29-residue GHRH analog > Manpage-style reference on sermorelin (GHRH 1-29 NH2): mechanism, half-life, FDA history, current US compounding status. Independent editorial summaries of the published record. sermorelin — synthetic 29-residue GHRH analog; growth-hormone-releasing factor (GRF) (1-29) amide. ## TLDR Sermorelin is a synthetic copy of the first 29 amino acids of the hypothalamic hormone that tells the pituitary gland to release growth hormone (GH). It does not supply GH directly. It signals the pituitary, which keeps the body's own feedback brakes — somatostatin and IGF-1 (a downstream hormone the liver makes in response to GH) — operating normally. It was once an FDA-approved drug (Geref, NDA 20-443) for children with a diagnosed GH shortage. That product was pulled from the US market in 2008 for commercial reasons, not safety concerns. It is now compounded prescription-only [1][2]. Adult anti-aging and body-composition use is off-label; the evidence base for those goals is thin and has been publicly called "not yet ready for prime time" [20]. It is prohibited in sport under WADA S2 [13]. What people anecdotally report — including the downsides — is on [the effects page](/effects). ## SYNOPSIS Compound: sermorelin. Class: GHRH receptor agonist. Form: hGRF(1-29)NH2, acetate salt. Length: 29 amino acids. Molecular weight: 3357.93 Da. Molecular formula: C149H246N44O42S. Plasma half-life: 11-12 min [10]. Route in published trials: subcutaneous (treatment); intravenous (diagnostic) [3][4][10]. US regulatory status: previously approved as two finished-drug formulations — diagnostic 0.05 mg (NDA 19-863, 1990) and therapeutic 0.5/1.0 mg (NDA 20-443, 1997) [1]. Both formulations were voluntarily withdrawn by the sponsor in 2008 [2]. The FDA determined in 2013 that the withdrawals were for commercial reasons, not safety or efficacy [2]. As of 2025, sermorelin acetate is available only as a compounded preparation through state-licensed 503A pharmacies and 503B outsourcing facilities, under the FDA's January 2025 interim policy on 503A bulk drug substances [16][17]. ## DESCRIPTION Sermorelin is the 29-residue N-terminal fragment of native human growth hormone-releasing hormone (GHRH 1-44), C-terminally amidated. The (1-29) fragment retains essentially full biological activity at the pituitary GHRH receptor — the shortest GHRH segment that still triggers somatotroph activation [3]. Because sermorelin is a secretagogue and not a hormone replacement, it acts on the pituitary's own GH machinery rather than supplying GH directly. The pituitary remains the source. Normal feedback by somatostatin and IGF-1 is preserved. The GH pulse it triggers is bounded by the body's physiological ceiling [3][7][10]. The most widely cited human dataset is the 1990s FDA-approval-supporting pediatric trials — 30 μg/kg subcutaneous nightly in children with idiopathic growth hormone deficiency, sustained increase in height velocity through 12-36 months [3]. A smaller but well-characterized aging-population literature followed: 10 μg/kg nightly for 16 weeks in adults 55-71 produced gains in skin thickness, lean body mass (+1.26 kg in men), and insulin sensitivity [6]; 2 mg nightly for 6 weeks in elderly men produced IGF-1 elevation by 2 weeks, sustained through 12 weeks [7]. ## WHY THIS SITE EXISTS Search for sermorelin online and the first ten results are clinics. This site is not one. It is an editorial reading room — a terminal-style summary of the published peer-reviewed and regulatory record, written for researchers, clinicians, science writers, and anti-doping analysts who want the primary sources without the upsell. The organization follows the structure of a Unix manpage. NAME, SYNOPSIS, DESCRIPTION, MECHANISM, PHARMACOKINETICS, HISTORY, SEE ALSO, BUGS, REFERENCES. Each quantitative claim cites a real trial or regulatory document. The references page lists all 19 sources with DOIs and PubMed/PMC URLs. What is here: mechanism, pharmacokinetics, the pediatric and aging-population trial record, the FDA approval-and-withdrawal sequence, the current 503A compounding status, the WADA prohibition, and the analytical methods used in doping control. What is not here: dosing recommendations, supplier links, comparisons to current peptide products, or any claim about how sermorelin should be used outside research and historical clinical contexts. ## SEE ALSO [research](/research) — full mechanism, pediatric trials, aging-population studies, and the GHRH+GHRP synergy literature. [dosage](/dosage) — research-context dose ranges from the FDA-approved pediatric regimen, the adult diagnostic provocation, the Khorram aging study, and the Vittone elderly-men pharmacodynamic study. [faq](/faq) — short answers to common questions about sermorelin, its history, and its current status. [references](/references) — full numbered citation list with DOIs. [about](/about) — editorial standards, what this site is and is not. [contact](/contact) — corrections, source submissions, takedown requests. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # Sermorelin reported effects and safety: what the record shows > Sermorelin effects and safety read from the GHRH(1-29) record: measured trial outcomes, what research-use communities report (anecdotal), and the cautions that apply. No doses. Measured outcomes, community-reported signals (labeled anecdotal), and the cautions grounded in the record — kept in separate sections. ## TLDR: what sermorelin actually does Plain words first. Sermorelin tells the pituitary gland — a small gland at the base of the brain — to release the body's own growth hormone (GH) in its normal pulsing rhythm. It is not GH itself. Because it works upstream, the body's own feedback brakes stay on: rising GH triggers somatostatin (the off-switch) and rising IGF-1 (a downstream liver hormone that carries out many of GH's jobs) sends a long feedback loop back to the hypothalamus [3][10]. The ceiling is the body's, not a fixed dose. What the clinical trials actually measured is narrow: faster growth in children with a documented GH shortage [22], and GH/IGF-1 returning toward younger-adult values in older men over a couple of weeks [23]. The popular framing — fat loss, sleep, "anti-aging" — is mostly not settled by long-term controlled trials [20]. The sections below keep the cited trial findings strictly separate from what people anecdotally report. ## What people report The following signals come from research-use and telehealth communities — **anecdotal, not clinical evidence**. They are recorded here for honest context; they are not trial outcomes, and no doses are attached. **Very commonly reported — benefits:** Deeper, more restful sleep and vivid dreams. The most-mentioned reason people try sermorelin. They describe falling asleep faster, sleeping more deeply, and noticing vivid dreaming within the first couple of weeks. This fits sermorelin's mechanism — GH is released mainly during deep sleep, and GHRH has physiologic sleep-promoting effects [15]. **Frequently reported — benefits:** More daytime energy and a sense of recovery; gradual body-fat reduction (particularly around the midsection) over several months. Results vary considerably; people frame it as a slow gradual shift, not a sudden change. **Occasionally reported — benefits:** Slightly better muscle tone, firmer-feeling skin, and a general sense of well-being after several months. A recurring community theme is that sermorelin is a "slow burn" — the first month can feel uneventful, with changes arriving in the second or third month. **Very commonly reported — adverse:** Injection-site redness, itching, swelling, or a small welt. Usually fades within a couple of hours. Matches what controlled GHRH studies describe [24][25]. **Frequently reported — adverse:** Short-lived headache, facial flushing, lightheadedness, or mild nausea, mostly in the first week or two. **Occasionally reported — adverse:** Mild fluid retention in ankles, hands, or face; increased appetite; drowsiness after the bedtime dose. **Rarely reported — adverse:** Tingling or numbness in the fingers (attributed to fluid pressing on nerves); slightly higher blood sugar in pre-diabetic or metabolically compromised individuals. ## Safety & cautions **Anti-aging benefit not proven.** Using growth-hormone secretagogues to prevent or treat the effects of aging is not yet justified by the evidence. An Annals of Internal Medicine editorial explicitly concluded it is "not yet ready for prime time" [20]. Anti-aging and body-composition use is best read as investigational, not established benefit. **Theoretical cancer consideration (mechanistic).** Growth hormone and IGF-1 are mitogenic — they encourage cell growth and division. Chronically raising them is theorized to carry an oncologic-risk consideration for any GH-axis intervention [21]. Sermorelin acts through the body's own feedback-regulated, pulsatile release, which may temper how high IGF-1 climbs, but this theoretical concern has not been resolved by long-term human data. **Blood-sugar and glucose tolerance.** GH can oppose insulin, so raising it may nudge blood sugar upward in susceptible people. In a study of a long-acting GHRH peptide, repeated dosing was associated with some impairment of glucose tolerance in elderly subjects [26]. People who are older, pre-diabetic, or have metabolic syndrome should monitor glucose. **Injection-site reactions and mild metabolic shifts.** Across human studies of GHRH(1-29) and related peptides, mild injection-site irritation is the most consistent side effect; a small number of participants showed transient changes such as a temporary rise in blood lipids that resolved [24][25][27]. **Off-target pituitary hormones (minor, cited).** In a study of short children, an intravenous GHRH dose caused small, short-term rises in other pituitary hormones — prolactin, LH, and FSH [28]. The effect was minor, but the pituitary is not a single isolated switch. **Continuous dosing can blunt the response.** The GH axis is built to fire in pulses. When GHRH(1-29) was given as a continuous infusion in children, the response faded after a few months, with one child's secretion fully suppressed [29]. Steady around-the-clock exposure can desensitize the pituitary. **Gray-market product quality.** Much of the sermorelin sold outside licensed pharmacy supply chains comes from an unregulated market. Critical reviews note that such peptide products are frequently mislabeled or contaminated, and rigorous safety data for unapproved use are scarce [30][31]. **Prohibited in sport.** GHRH analogs, including sermorelin, are on the WADA Prohibited List (S2), banned at all times. Validated detection methods exist [32]. Athletes face anti-doping consequences [13]. ## HISTORY: then and now Sermorelin has a genuine FDA-approval history that is often misstated. It was approved as Geref (NDA 020443) and used both as a diagnostic agent — a single intravenous dose to test pituitary GH reserve — and as a treatment to accelerate growth in children with GH deficiency. A multicenter trial in GH-deficient children showed that once-daily injections sped up height growth in the first year [22][33]. Review articles documented its diagnostic and pediatric treatment roles [33]. In 2008 the branded product was withdrawn from the US market for commercial reasons, not because of any safety or effectiveness problem [1][2]. Clinicians at the time noted the resulting absence of a commercially available GHRH agent and turned to alternative pituitary-stimulation tests [34]. Today sermorelin is no longer sold as an approved branded drug; it is prepared by compounding pharmacies. Under the FDA's interim Section 503A policy (issued January 2025) it is treated as a Category 1 bulk drug substance [35]. The current anti-aging and wellness use of compounded sermorelin is off-label and is not the same as its former FDA-approved indication. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # sermorelin — research record: mechanism, pediatric trials, aging studies, synergy > The published research literature on sermorelin (GHRH 1-29 NH2): receptor mechanism, pulsatile GH release, FDA-approval-supporting pediatric trials, aging-population studies, GHRH+GHRP synergy, and the 2024 WADA detection methods. Mechanism, pharmacokinetics, pediatric clinical record, aging studies, synergy with GHS-R agonists, and the analytical chemistry now used to detect sermorelin in athlete urine. ## SYNOPSIS: the research record The published record on sermorelin divides cleanly into two literatures. The first is pediatric: FDA-approval-supporting trials in children with idiopathic GH deficiency showed consistent, sustained increases in height velocity with once-daily subcutaneous dosing [3]. The second is aging-population pharmacodynamics: short trials in older adults showed GH and IGF-1 returning toward younger-adult values, with modest body-composition changes [6][7]. A third thread is mechanistic: because sermorelin acts via the pituitary receptor (GHRH-R) rather than supplying exogenous GH, physiological feedback is preserved — the pituitary remains the source, and somatostatin still caps the ceiling [3][10]. This property underpins both the diagnostic use (intact-pituitary reserve test) and the editorial argument for sermorelin as a physiologic secretagogue approach [21]. WADA-detection methods are validated. The sections below lay out each thread with citations. ## MECHANISM Sermorelin is a true GH secretagogue. It binds GHRHR — a class-B G-protein-coupled receptor expressed on anterior pituitary somatotrophs — and triggers a Gs / adenylyl cyclase / cAMP / PKA cascade. The cascade does two things: it stimulates GH gene transcription, and it releases pre-formed GH from secretory vesicles [3][10]. The GH pulse this produces drives hepatic IGF-1 synthesis through the GH receptor's JAK2-STAT5 axis [3]. IGF-1 is the principal blood biomarker of GH-axis activation and the primary downstream mediator of GH's anabolic effects [7]. Because the pituitary remains the source of GH, two physiological constraints stay intact. Somatostatin negative feedback continues to throttle output. Rising IGF-1 continues to provide long-loop feedback. Sermorelin cannot push GH past these ceilings the way exogenous recombinant GH can [3][10][12]. The peptide's short plasma half-life — approximately 11-12 minutes [10] — is a deliberate design property of the (1-29) fragment, not a limitation. A short-acting GHRH agonist produces a discrete pulse rather than tonic stimulation. The downstream GH pulse persists for 2-4 hours after a single subcutaneous dose, despite essentially complete clearance of the peptide itself by 60 minutes [10]. ## PHARMACOKINETICS After a 2 mg subcutaneous dose, peak plasma sermorelin concentration is reached at 5-20 minutes [10]. Less than 5% of the dose remains detectable in plasma at 60 minutes [10]. Adult clearance is 2.4-2.8 L/min [10]. The plasma half-life is approximately 11-12 minutes after both subcutaneous and intravenous administration [10]. Class comparison: sermorelin t1/2 ~12 min, tesamorelin t1/2 ~26 min after SC dosing, CJC-1295 with DAC several days because of albumin bioconjugation [19]. Sermorelin's short half-life is what produces a discrete physiological GH pulse, in contrast to the more sustained elevation profiles of the longer-acting analogs [19]. Stability: lyophilized sermorelin acetate is stable when refrigerated (2-8°C) and protected from light. Reconstituted aqueous solution should be refrigerated and used promptly. The C-terminal amide and unprotected backbone make the peptide sensitive to proteolytic and oxidative degradation. The (1-29) fragment is more chemically stable than full-length GHRH (1-44) but is far shorter-acting than the modified GRF(1-29) backbone used in longer-acting analogs. ## PEDIATRIC GROWTH-HORMONE-DEFICIENCY RECORD The FDA-approval-supporting clinical dataset was pediatric. Once-daily subcutaneous sermorelin at 30 μg/kg given at bedtime produced sustained increases in height velocity in prepubertal children with idiopathic growth hormone deficiency [3]. The velocity gain was maintained through 12 months of treatment and reported through 36 months in extension cohorts. Slow-growing, shorter children with delayed bone age responded best [3]. A parallel pediatric study in children with idiopathic short stature — not classified as GH-insufficient — used 20 μg/kg subcutaneously twice daily for 12 months. Height velocity rose throughout treatment and returned to pretreatment values after cessation, confirming GHRH-axis dependence of the response [5]. Earlier mechanistic work in GH-deficient children compared continuous subcutaneous GHRH(1-29)NH2 infusion against intermittent injection over 6 months. Both promoted linear growth; the comparison demonstrated that pulsatile or repeated stimulation patterns are required for optimal somatotropic activation [8]. The pediatric record has been largely supplanted in clinical practice by recombinant human growth hormone, which produces larger and more predictable height-velocity gains in head-to-head comparisons. Sermorelin's responder rate and effect size were consistently smaller than rhGH's — a key reason the original sponsor exited the market in 2008 [2]. ## AGING-POPULATION STUDIES A smaller but distinct adult literature looked at GHRH(1-29) in older adults. Khorram et al. (1997) gave a sermorelin-equivalent analog at 10 μg/kg subcutaneously nightly for 16 weeks to healthy adults aged 55-71. The trial reported significant increases in skin thickness in both sexes, a +1.26 kg increase in lean body mass in men, improved insulin sensitivity, and self-reported gains in general well-being and libido in men [6]. Vittone et al. (1997) gave 2 mg nightly subcutaneously for 6 weeks to healthy elderly men aged 64-76. IGF-1 elevation was evident by 2 weeks and sustained through 12 weeks, with measurable IGF-1 still present at 16 weeks post-cessation before returning to baseline. Lean body mass increased significantly in the longer-treated subgroup. The regimen was well tolerated [7]. Neuroendocrine work in healthy adults established that GHRH activity correlates with increased duration and intensity of slow-wave (NREM stage 3-4) sleep — the mechanistic basis for clinical observations that sermorelin-treated patients commonly report subjective sleep-quality improvements [15]. A 2012 trial in adults with mild cognitive impairment and healthy older adults tested tesamorelin (a GHRH(1-44) analog of the same receptor class as sermorelin) at 1 mg SC daily for 20 weeks. The trial reported a significant favorable effect on executive function vs placebo — a class-level signal for cognitive plausibility in GHRH agonists. Sermorelin itself has not been tested in a comparable powered cognitive RCT [14]. ## GHRH + GHRP SYNERGY Co-administration of a GHRH analog with a GHS-R1a (ghrelin-receptor) agonist produces a synergistic — not merely additive — GH secretory response, several-fold greater than either agent alone [9]. The original demonstration paired intravenous GHRH at 1 μg/kg with intravenous GHRP-6 at 1 μg/kg in healthy human volunteers. GH peaks under combined stimulation were several-fold larger than either alone [9]. The pharmacodynamic basis is that the two receptors converge on the somatotroph through distinct second-messenger pathways. GHRHR signals through Gs / adenylyl cyclase / cAMP / PKA. GHS-R1a signals through phospholipase C / IP3 / intracellular calcium. Convergence on a single secretory cell produces a multiplicative output [9]. This dual-receptor pharmacology is the published rationale for the widely studied 'GHRH + GHRP' pairing in research-program and clinical-compounding protocols. The most commonly described pairings replace the first-generation GHRP-6 with the selective pentapeptide ipamorelin, which delivers the GH-releasing synergy without the cortisol or prolactin elevation seen with earlier GHRPs. ## DIAGNOSTIC USES Intravenous sermorelin at 1 μg/kg was the FDA-approved diagnostic provocative test for growth hormone deficiency in children [1][4]. It produces a rapid and relatively specific GH response with fewer false positives than several alternative provocative tests [4]. The diagnostic protocol samples GH at baseline and at 15, 30, 45, and 60 minutes post-injection. Subnormal responses to additional non-GHRH stimuli are required to confirm hypothalamic versus pituitary etiology, because hypothalamic GHRH-deficient patients may still respond to exogenous GHRH [4]. In adults, the combination of intravenous GHRH (sermorelin) at 1 μg/kg plus intravenous L-arginine at 0.5 g/kg over 30 min became one of the most accurate provocative tests for adult GH deficiency [11]. It was unaffected by age or sex when appropriate BMI-adjusted cutoffs were applied, and at least as sensitive as the insulin tolerance test — the historical gold standard [11]. The 2008 US withdrawal of sermorelin supply reduced availability and shifted adult-GHD diagnostic practice toward the glucagon stimulation test and, more recently, macimorelin [11]. ## SAFETY RECORD Adverse events reported in sermorelin clinical trials are predominantly mild and local: transient facial flushing, redness or pain or swelling at the injection site, occasional headache, dizziness, and nausea [12]. Serious adverse events were rare across the pediatric and adult studies that supported FDA approval [12]. The safety record was preserved when the product was withdrawn for commercial reasons in 2008 — the 2013 Federal Register finding explicitly affirmed that withdrawal was not for safety or efficacy concerns [2]. Long-term (multi-year) safety of off-label sermorelin use in healthy aging adults has not been characterized in controlled trials. Theoretical concerns about sustained IGF-1 elevation — insulin resistance, edema, joint discomfort, neoplasia signaling — remain unresolved by the existing dataset. ## ANALYTICAL DETECTION Sermorelin is listed under Section S2 of the World Anti-Doping Code Prohibited List — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — prohibited at all times for any athlete subject to the WADA Code [13][18]. Validated nano-LC Orbitrap mass-spectrometric methods detect sermorelin and related GHRH analogs in athlete urine at sub-ng/mL concentrations [18]. The 2024 method paper addressed the analytical challenges of low urinary peptide concentration and freeze-thaw instability, and is now deployed routinely in doping control [18]. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # sermorelin — dose ranges in the published trial record > Dose ranges documented in the FDA-approved pediatric regimen, the adult diagnostic provocation, the Khorram aging study, and the Vittone elderly-men pharmacodynamic study. Research and historical-clinical context only. Dose ranges as documented in the FDA-approved pediatric regimen, the adult diagnostic provocation, and the published aging-population studies. Historical and research context. ## WHAT THIS PAGE DOCUMENTS This page documents dose ranges that appear in the published peer-reviewed and regulatory record for sermorelin. It does not recommend a dose. It is a structured summary of what was studied — by whom, at what dose, in what population, by what route, for how long — with citations. Sermorelin previously held FDA approval for two specific indications with labeled dose ranges. The product is no longer marketed as a finished FDA-approved drug [1][2]. Compounded preparations available through 503A pharmacies are not reviewed by FDA for safety, efficacy, or quality before patient use [16]. What you are reading is the historical and research-context record, not a protocol. ## WHAT THIS PAGE IS This page documents the dose ranges that appear in the published peer-reviewed and regulatory record for sermorelin. It does not recommend a dose. It does not describe a current treatment protocol. It is a structured summary of what was studied, by whom, at what dose, in what population, by what route, for how long — with citations. Sermorelin previously held FDA approval for two specific indications (pediatric GH-deficiency diagnosis and treatment) with labeled dose ranges. The product is no longer marketed as a finished FDA-approved drug. Compounded preparations available through 503A pharmacies and 503B outsourcing facilities are not reviewed by FDA for safety, efficacy, or quality before patient use [16]. ## FDA-APPROVED PEDIATRIC TREATMENT DOSE 30 μg/kg subcutaneously, nightly at bedtime — the dosing schedule used to support FDA approval of the 0.5 mg and 1.0 mg therapeutic formulations under NDA 20-443 (1997) for the treatment of idiopathic growth hormone deficiency in children [1][3]. Sustained increases in height velocity were documented through 12-36 months of treatment in extension cohorts [3]. ## FDA-APPROVED PEDIATRIC DIAGNOSTIC DOSE 1 μg/kg as a single intravenous bolus, with serum GH sampling at baseline and at 15, 30, 45, and 60 minutes post-injection — the provocative diagnostic protocol that supported FDA approval of the 0.05 mg diagnostic ampule under NDA 19-863 (1990) [1][4]. The test assesses pituitary somatotroph reserve; subnormal responses to additional non-GHRH stimuli are required to confirm hypothalamic versus pituitary etiology because hypothalamic GHRH-deficient patients may still respond to exogenous GHRH [4]. ## ADULT GHD COMBINED DIAGNOSTIC DOSE 1 μg/kg intravenous sermorelin combined with 0.5 g/kg intravenous L-arginine infused over 30 minutes — the GHRH-arginine stimulation test, validated for adult GH-deficiency diagnosis with accuracy at least comparable to the insulin tolerance test [11]. Used in clinical endocrinology as a single-occasion diagnostic procedure, not a chronic treatment. The 2008 US sermorelin withdrawal reduced availability of this test and shifted clinical practice toward glucagon stimulation and macimorelin [11]. ## AGING-POPULATION PHARMACODYNAMIC DOSES Khorram et al. 1997 — 10 μg/kg subcutaneously nightly for 16 weeks in healthy adults aged 55-71. The regimen produced significant increases in skin thickness in both sexes and a +1.26 kg increase in lean body mass in men, with improved insulin sensitivity and self-reported gains in well-being and libido in men [6]. Vittone et al. 1997 — 2 mg fixed-dose subcutaneously nightly for 6 weeks in healthy elderly men aged 64-76. IGF-1 elevation was evident by 2 weeks and sustained through 12 weeks; lean body mass increased significantly in the longer-treated subgroup. The regimen was well tolerated [7]. ## PEDIATRIC IDIOPATHIC SHORT STATURE DOSE Kirk et al. 1994 — 20 μg/kg subcutaneously twice daily for 12 months in prepubertal children with idiopathic short stature not classified as GH-insufficient. Height velocity increased throughout the treatment period and returned to pretreatment values after cessation, confirming GHRH-axis dependence [5]. This was a research study, not an FDA-approved indication. ## PHARMACOKINETIC NUMBERS Plasma half-life ~11-12 minutes after both subcutaneous and intravenous administration [10]. Peak plasma concentration 5-20 minutes after a 2 mg subcutaneous dose [10]. Less than 5% of an administered dose remains detectable in plasma at 60 minutes [10]. Adult clearance 2.4-2.8 L/min [10]. Downstream GH pulse persists for 2-4 hours after a single dose [10]. Class comparison: sermorelin t1/2 ~12 min; tesamorelin t1/2 ~26 min after SC dosing; CJC-1295 DAC several days due to albumin bioconjugation [19]. ## STABILITY AND HANDLING Lyophilized sermorelin acetate is stable when stored refrigerated (2-8°C) and protected from light. Reconstituted aqueous solution should be refrigerated and used promptly. The C-terminal amide and unprotected backbone make sermorelin sensitive to proteolytic and oxidative degradation. Repeated freeze-thaw cycles or warm-temperature exposure degrade biological activity. The (1-29) fragment is more chemically stable than full-length GHRH (1-44) but is far shorter-acting than the modified GRF(1-29) backbone used in CJC-1295. ## STDERR Compounded preparations are not FDA-reviewed for safety, efficacy, or quality before patient use [16]. The off-label use of sermorelin for anti-aging, body-recomposition, sleep, and 'longevity' purposes in healthy adults is not supported by adequately powered randomized controlled trials in those populations. Sermorelin is prohibited at all times by WADA Section S2 — any athlete subject to WADA testing using sermorelin without a granted Therapeutic Use Exemption commits an Anti-Doping Rule Violation [13]. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # sermorelin — frequently asked questions > Common questions about sermorelin: what it is, how it works, why the original FDA-approved product was withdrawn, current US compounding status, half-life, and the difference between sermorelin and other GHRH analogs. Short answers to the questions readers most often arrive with. Direct, cited, and updated through the January 2025 FDA interim 503A policy. ## What is sermorelin and what is it derived from? Sermorelin is the synthetic 29-residue C-terminally amidated fragment of human growth hormone-releasing hormone — written chemically as hGRF(1-29)NH2 [3]. Native GHRH is a 44-amino-acid hypothalamic peptide. The first 29 amino acids retain essentially full biological activity at the pituitary GHRH receptor, which is why the (1-29) fragment became the clinical compound [3]. The molecular formula is C149H246N44O42S; the molecular weight is 3357.93 Da. Sermorelin is the only true GHRH agonist in this analog family that received FDA finished-drug approval [1]. ## How does sermorelin work in the body? Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs and triggers a Gs / adenylyl cyclase / cAMP / PKA second-messenger cascade [3][10]. The cascade stimulates GH gene transcription and releases pre-formed GH from secretory vesicles. The released GH then drives hepatic IGF-1 synthesis through the GH receptor's JAK2-STAT5 axis [3]. Because the pituitary remains the GH source, somatostatin and IGF-1 negative feedback stay intact — sermorelin cannot push GH past the physiological ceiling in the way exogenous recombinant GH can [3][10][12]. ## What is the half-life of sermorelin? Approximately 11-12 minutes in plasma after either subcutaneous or intravenous administration [10]. Peak plasma concentration is reached 5-20 minutes after a 2 mg subcutaneous dose, and less than 5% of the dose remains detectable in plasma by 60 minutes [10]. Adult clearance is 2.4-2.8 L/min [10]. Despite the short circulating half-life, the GHRHR-mediated GH pulse it triggers persists for 2-4 hours after a single injection — the peptide is consumed quickly, but its downstream signal lasts much longer [10]. ## What was the original FDA-approved sermorelin and why was it discontinued? Sermorelin acetate received two FDA approvals: a 0.05 mg diagnostic injection under NDA 19-863 in 1990, and 0.5 mg and 1.0 mg therapeutic vials under NDA 20-443 in 1997, the latter indicated for the treatment of idiopathic growth hormone deficiency and growth failure in children [1]. The sponsor submitted requests to withdraw both formulations in 2008 (the diagnostic ampule on July 11, 2008 and the therapeutic vials on December 2, 2008) [2]. The FDA published a formal determination in the March 4, 2013 Federal Register that the withdrawals were for commercial reasons and not for reasons of safety or effectiveness [2]. That preservation of the safety/efficacy record is what historically supported continued pharmacy compounding of sermorelin under Section 503A of the Federal Food, Drug, and Cosmetic Act [16]. ## Is sermorelin still legal in the United States in 2025? No FDA-approved finished-drug sermorelin product is currently marketed in the United States. The original formulations were withdrawn in 2008 [2]. Sermorelin acetate is currently prepared under 503A patient-specific compounding by state-licensed pharmacists and 503B outsourcing facility manufacturing, in both cases under physician prescription [16]. The October 29, 2024 FDA Pharmacy Compounding Advisory Committee briefing materials reviewed the broader GH-secretagogue peptide class and articulated the regulatory framework under which sermorelin — by virtue of its preserved approval record — remains compoundable while several related research peptides did not advance to the 503A bulks list [17]. The January 7, 2025 FDA interim policy on 503A bulk drug substances maintains sermorelin's pathway under existing pharmacy law [16]. Compounded preparations are not reviewed by FDA for safety, efficacy, or quality before patient use [16]. ## How is sermorelin different from CJC-1295 and tesamorelin? All three are GHRH receptor agonists. The principal difference is half-life [19]. Sermorelin: plasma t1/2 ~12 minutes [10]. Tesamorelin: plasma t1/2 ~26 minutes after subcutaneous dosing [19]. CJC-1295 with DAC (drug affinity complex): plasma t1/2 of several days, achieved through covalent bioconjugation to albumin [19]. Sermorelin's short half-life produces a discrete physiological GH pulse that closely mimics endogenous pulsatile release. Tesamorelin's modestly longer half-life is still pulsatile but with a broader peak. CJC-1295 with DAC produces a sustained elevation profile rather than a pulse — pharmacologically a different mode of GHRHR engagement [19]. Regulatory status also differs: sermorelin and tesamorelin both have FDA approval histories (tesamorelin remains marketed for HIV-associated lipodystrophy); CJC-1295 has no FDA-approved finished drug product. ## Why is sermorelin often paired with ipamorelin in research protocols? Co-administration of a GHRH analog with a GHS-R1a (ghrelin-receptor) agonist produces a synergistic — not merely additive — GH secretory response, several-fold greater than either agent alone [9]. The two receptors signal through distinct second-messenger pathways (cAMP/PKA for GHRHR; phospholipase C / IP3 / calcium for GHS-R1a) but converge on the same somatotroph cell. Combined activation generates a GH peak that is multiplicative rather than additive [9]. Foundational human work used GHRP-6 with GHRH [9]; modern research and compounding protocols typically substitute the selective pentapeptide ipamorelin, which delivers the GH-releasing synergy without the cortisol or prolactin elevation associated with earlier GHRPs. ## What did the original pediatric trials show? Once-daily subcutaneous sermorelin at 30 μg/kg administered at bedtime produced significant, sustained increases in height velocity in prepubertal children with idiopathic growth hormone deficiency [3]. The velocity gain was maintained through 12 months of treatment and reported through 36 months in extension cohorts. Slow-growing, shorter children with delayed bone age responded best [3]. A parallel trial in children with idiopathic short stature (not classified as GH-insufficient) used 20 μg/kg subcutaneously twice daily for 12 months — height velocity rose throughout treatment and returned to pretreatment values after cessation, confirming GHRH-axis dependence [5]. Earlier mechanistic work demonstrated that continuous subcutaneous infusion of GHRH(1-29) also promotes growth in GH-deficient children, but compared with intermittent injection showed that pulsatile stimulation patterns are required for optimal somatotropic activation [8]. ## What did the older-adult studies find? Two studies dominate the published older-adult record. Khorram et al. 1997: 10 μg/kg subcutaneously nightly for 16 weeks in adults aged 55-71. Significant increases in skin thickness in both sexes, +1.26 kg lean body mass in men, improved insulin sensitivity, and self-reported gains in well-being and libido in men [6]. Vittone et al. 1997: 2 mg fixed-dose subcutaneously nightly for 6 weeks in healthy elderly men aged 64-76. IGF-1 elevation was evident by 2 weeks and sustained through 12 weeks; lean body mass increased in the longer-treated subgroup; the regimen was well tolerated [7]. Both trials were short — 6 and 16 weeks respectively. The aging dataset is not the FDA-approval dataset; the approved indication remained pediatric GHD throughout the drug's market life [1]. ## What are the documented side effects of sermorelin in clinical trials? Adverse events were predominantly mild and local: transient facial flushing, redness or pain or swelling at the injection site, occasional headache, dizziness, and nausea [12]. Serious adverse events were rare across the pediatric and adult trials supporting FDA approval [12]. The safety record was preserved when the product was withdrawn for commercial reasons in 2008 — the 2013 FDA determination explicitly affirmed the withdrawal was not for safety or efficacy concerns [2]. Long-term (multi-year) safety of off-label sermorelin use in healthy aging adults has not been characterized in controlled trials. Theoretical concerns about sustained IGF-1 elevation — insulin resistance, edema, joint discomfort, neoplasia signaling — remain unresolved by the existing dataset. ## Is sermorelin prohibited for athletes? Yes. The 2025 World Anti-Doping Code Prohibited List continues to list sermorelin under Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — prohibited at all times (in-competition and out-of-competition) for any athlete subject to the WADA Code [13]. Validated nano-LC Orbitrap mass-spectrometric methods detect sermorelin and related GHRH analogs in athlete urine at sub-ng/mL concentrations [18]. The 2024 method paper addressed the analytical challenges of low urinary peptide concentration and freeze-thaw instability and is now deployed routinely in doping control [18]. Use without a granted Therapeutic Use Exemption constitutes an Anti-Doping Rule Violation [13]. ## Where can researchers find published information about sermorelin online? The primary sources are PubMed and PMC for the peer-reviewed clinical literature, the FDA Federal Register for the NDA and withdrawal documentation [1][2], the FDA Pharmacy Compounding Advisory Committee briefing materials and meeting transcripts for current regulatory positioning [17], and the WADA website for the current Prohibited List [13]. The references page on this site links to all 19 cited sources with DOIs and direct URLs. The Prakash & Goa 1999 BioDrugs review and the Ishida et al. 2020 JCSM growth-hormone-secretagogues review are useful narrative entry points to the full historical literature [3][19]. ## Does sermorelin make you grow taller as an adult? No. The growth-velocity studies were in prepubertal children with open growth plates [3][5][8]. Once growth plates fuse at the end of puberty, GH and IGF-1 elevation cannot increase linear stature. The aging-population studies in adults reported body-composition and skin-thickness changes — not height changes [6][7]. ## Can sermorelin work if the pituitary is damaged? Sermorelin cannot fully restore GH levels in patients whose pituitary somatotrophs are functionally absent — for example after pituitary tumor resection, after radiation therapy involving the sella, or in congenital somatotroph aplasia. The secretagogue mechanism requires an intact pituitary capable of producing and storing GH. This is one of the reasons recombinant human growth hormone — which supplies the hormone directly — supplanted sermorelin for most pediatric GHD treatment after the 2008 withdrawal. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # sermorelin — references > Complete numbered citation list with DOIs and PubMed/PMC URLs for every source cited across the onlinesermorelin reading room. Nineteen sources. FDA Federal Register documents, the foundational pediatric and adult clinical trials, the GHRH+GHRP synergy work, the WADA Prohibited List, and the 2024-2025 regulatory updates. ## Primary regulatory sources References [1], [2], [16], [17] are FDA Federal Register and FDA Pharmacy Compounding Advisory Committee primary documents. Reference [13] is the WADA Prohibited List. These are the authoritative sources for current US regulatory status and global anti-doping status. See the full numbered list below. ## Foundational pediatric and adult clinical trials References [3], [4], [5], [7], [8] are the published clinical trials that supported FDA approval and the parallel pediatric studies in idiopathic short stature. Reference [6] is the Khorram aging study. Reference [11] is the GHRH-arginine adult diagnostic combination. ## Mechanism and class pharmacology References [9], [10], [12], [14], [15], [19] cover mechanism, pharmacokinetics, the GHRH+GHRP synergy, slow-wave sleep regulation, the tesamorelin cognitive trial as class-level comparator, and the head-to-head half-life comparison across the GHRH agonist class. ## Analytical chemistry and anti-doping Reference [18] is the 2024 nano-LC Orbitrap mass-spectrometric method paper validated to WADA technical-document specifications for sermorelin and related GHRH analogs in athlete urine. ## References [1] U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, Vol. 78, No. 42. 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams [2] U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams [3] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/ [4] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (diagnostic-test review section). BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/ [5] Kirk JM, Trainer PJ, Majrowski WH, Murphy J, Savage MO, Besser GM. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clinical Endocrinology. 1994;41(4):487-493. https://pubmed.ncbi.nlm.nih.gov/7955460/ [6] Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. https://academic.oup.com/jcem/article-abstract/82/5/1472/2823341 [7] Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: Clinical and Experimental. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9258281/ [8] Smith PJ, Brook CGD, Rivier J, Vale W, Thorner MO. Continuous subcutaneous GHRH(1-29)NH2 promotes growth hormone secretion and growth in children with growth hormone deficiency. Clinical Endocrinology. 1986;25(1):35-44. https://pubmed.ncbi.nlm.nih.gov/2140733/ [9] Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Combined administration of GHRH and GHRP-6 acts in synergy on growth hormone (GH) release in humans. Journal of Clinical Endocrinology and Metabolism. 1990;70(4):975-982. https://pubmed.ncbi.nlm.nih.gov/2107173/ [10] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (pharmacokinetics section). BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/ [11] Aimaretti G, Baffoni C, DiVito L, Bellone S, Grottoli S, Maccario M, Arvat E, Camanni F, Ghigo E. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. European Journal of Endocrinology. 2001;145(4):369-376. https://pubmed.ncbi.nlm.nih.gov/11572322/ [12] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (safety profile section). BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/ [13] World Anti-Doping Agency. World Anti-Doping Code International Standard — The 2025 Prohibited List. https://www.wada-ama.org/en/prohibited-list [14] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/ [15] Steiger A, Guldner J, Hemmeter U, et al. Growth hormone-releasing hormone (GHRH) and sleep regulation. Psychoneuroendocrinology. 1992;17(2-3):125-137. https://pubmed.ncbi.nlm.nih.gov/1438644/ [16] U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry. Federal Register. 2025. https://www.federalregister.gov/documents/2025/01/07/2024-31546/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503a-of-the-federal-food-drug [17] U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee — Briefing Materials. FDA Briefing Materials. 2024. https://www.fda.gov/media/182088/download [18] Thomas A, Walpurgis K, Tretzel L, Brinkkotter P, Fussholler G, Gorgens C, Geyer H, Thevis M. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of Mass Spectrometry. 2024. https://pubmed.ncbi.nlm.nih.gov/38197510/ [19] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 [20] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Annals of Internal Medicine. 2008;149(9):677-679. https://pubmed.ncbi.nlm.nih.gov/18981489/ [21] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nature Reviews Endocrinology. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/ [22] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology and Metabolism. 1996;81(3):1189-1196. https://pubmed.ncbi.nlm.nih.gov/8772599/ [23] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/ [24] A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for the treatment of children with idiopathic GH deficiency. Acta Paediatrica Supplement. 1993. https://pubmed.ncbi.nlm.nih.gov/8329830/ [25] Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology and Metabolism. 1997;82(5):3590-3596. https://pubmed.ncbi.nlm.nih.gov/9141536/ [26] Maa M, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH release with preservation of pulsatility. European Journal of Endocrinology. 2005;153(1):15-22. https://pubmed.ncbi.nlm.nih.gov/16061831/ [27] Balber T, et al. Long-term therapy with a single daily subcutaneous dose of growth hormone releasing factor in children with growth hormone deficiency. Journal of Pediatric Endocrinology and Metabolism. 1994;7(4):303-313. https://pubmed.ncbi.nlm.nih.gov/7735367/ [28] Hindmarsh P, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones on pituitary hormone secretion in short children. Hormone Research. 1989;31(1-2):33-38. https://pubmed.ncbi.nlm.nih.gov/2515143/ [29] Smith PJ, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone in children with GH deficiency. Acta Paediatrica Supplement. 1993. https://pubmed.ncbi.nlm.nih.gov/8329829/ [30] Pedersen L, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and competitive athletes. Journal of Sports Medicine and Physical Fitness. 2026. https://pubmed.ncbi.nlm.nih.gov/41880199/ [31] Dhurat R, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Conditions: A Systematic Review. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/ [32] Thomas A, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021. https://pubmed.ncbi.nlm.nih.gov/34665524/ [33] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/ [34] Popovic V, et al. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or a blessing in disguise? Journal of Clinical Endocrinology and Metabolism. 2009;94(8):2756-2761. https://pubmed.ncbi.nlm.nih.gov/19509104/ [35] U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry. 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # about — onlinesermorelin editorial standards > onlinesermorelin is an independent editorial project that publishes summaries of the peer-reviewed and regulatory research literature on sermorelin. Not a clinic. Not a pharmacy. Not a vendor. onlinesermorelin is an independent editorial reading room — a structured summary of the published sermorelin record, written in a terminal-style register. Not a clinic. Not a pharmacy. Not a vendor. ## WHAT THIS SITE IS onlinesermorelin is an independent editorial project that publishes summaries of the peer-reviewed and regulatory research literature on sermorelin (GHRH 1-29 NH2). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The site is organized as a Unix manpage. Each major page maps to a manpage section — NAME, SYNOPSIS, DESCRIPTION, MECHANISM, PHARMACOKINETICS, HISTORY, SEE ALSO, BUGS, REFERENCES. The structure is the point: the published record on sermorelin is unusually well-documented (two FDA NDAs, a preserved Federal Register finding, a thirty-year clinical dataset, a precise pharmacokinetic profile, a clean WADA listing) and reads cleanly as a reference document rather than a sales page. ## WHAT 'ONLINE' MEANS HERE The 'online' modifier in onlinesermorelin.com is editorial framing — a position the publisher occupies relative to the literature. It signals an online-research-reading-room: the published record on sermorelin, brought into one searchable, structured, citation-anchored place that a researcher, science writer, anti-doping analyst, or curious reader can read without arriving on a wellness clinic landing page. It is not a claim that this site offers consultations, prescriptions, telehealth, dispensing, or any healthcare service. The 'online' modifier does not change that. We do not see patients, we do not write prescriptions, and we do not refer to clinics or compounding pharmacies. ## EDITORIAL STANDARDS Every quantitative claim on every page cites a real study from the published peer-reviewed literature or a regulatory primary document. The references page lists all 19 sources with DOIs and direct PubMed, PMC, FDA Federal Register, or WADA URLs. We do not invent research. We do not extrapolate beyond what the cited trial actually showed. Where evidence is class-level (for example the tesamorelin cognitive trial as a GHRH-class signal), we mark it as class-level rather than as a sermorelin finding. We do not name compounding pharmacies, telehealth providers, research-chemical vendors, or product brands. Trademarks of the original FDA-approved sermorelin product, its former sponsor, and recombinant human growth hormone brands are deliberately avoided — they are not necessary to summarize the published record, and naming them would shift the editorial register from documentary to commercial. We do not recommend doses. The dosage page documents what was studied — by whom, at what dose, in what population, by what route, for how long — with citations. It is a structured summary of the published record, not a protocol. ## WHAT THIS SITE IS NOT Not a clinic. Not a pharmacy. Not a telehealth provider. Not a supplier of sermorelin or any other peptide. Not affiliated with any compounding pharmacy or 503B outsourcing facility. Not affiliated with the former sponsor of the original FDA-approved sermorelin product or with any GH-related product manufacturer. Not medical advice. The site reports what the research literature and regulatory record say about sermorelin. Decisions about diagnosis, treatment, or use of any compound are between a person and their qualified healthcare provider — not us. ## CORRECTIONS Errors and source corrections are welcome. The contact page describes how to submit a correction. If a cited source is misrepresented, a regulatory status has changed, or a newer trial supersedes a finding we summarize, we want to know. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol. --- # contact — onlinesermorelin > How to reach onlinesermorelin with corrections, source submissions, takedown requests, or research-source recommendations. Not for medical advice or prescription requests. Corrections, source submissions, takedown requests, and research-source recommendations. Not for medical advice or prescription requests. ## WHAT TO WRITE ABOUT Use the form below to send a correction, suggest a peer-reviewed source we missed, flag a regulatory update we have not yet incorporated, or recommend an editorial improvement. What we read carefully: factual corrections with a source link; PubMed or PMC IDs of trials we missed; FDA Federal Register documents we have not cited; WADA Prohibited List updates; corrections to dosage-page entries; flags on outdated regulatory language. ## WHAT WE CANNOT HELP WITH We cannot answer questions about whether sermorelin is appropriate for an individual person, whether a particular pharmacy or compounding facility is legitimate, where to obtain sermorelin, what dose to take, or any other question that would require a clinician's judgment about an identifiable person's care. We are not a clinic, we do not employ clinicians, and we do not provide medical advice. We cannot recommend pharmacies, telehealth providers, research-chemical vendors, or supplier brands. We do not maintain such a list and would not publish one. ## FORM [Contact form — name, email, message, submit] ## DISCLAIMER This site is editorial commentary on publicly available research. A digest of the peer-reviewed and regulatory record — not a clinic, not a pharmacy, not a vendor, not medical advice. --- A terminal-style digest of the peer-reviewed and regulatory record — not a clinic, not a prescription, not a protocol.